Eligibility criteria
non-metastatic breast cancer
The study included premenopausal patients over the age of 18 with non-metastatic breast cancer and positive hormone receptor status who met the criteria for endocrine therapy All of the patients received chemotherapy regimen of AC4T4 (Adriamycin 60 mg/m2, Cyclophosphamide 600 mg/m2 – Docetaxel 75 mg/m2), and Tamoxifen for endocrine therapy. The exclusion criteria included the need to hysterectomy and oophorectomy, and participant’s unwillingness to continue participation.